Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Desensitization, Immunologic | 17 | 2021 | 574 | 2.35 | Why? |
| Hypersensitivity | 16 | 2021 | 1137 | 1.83 | Why? |
| Allergens | 9 | 2021 | 728 | 0.87 | Why? |
| Antigens, Dermatophagoides | 1 | 2018 | 25 | 0.75 | Why? |
| Cell Extracts | 1 | 2018 | 27 | 0.75 | Why? |
| Asthma | 12 | 2021 | 4383 | 0.70 | Why? |
| Rhinitis, Allergic | 5 | 2021 | 704 | 0.62 | Why? |
| Bronchi | 2 | 2018 | 1048 | 0.47 | Why? |
| TRPA1 Cation Channel | 2 | 2021 | 82 | 0.42 | Why? |
| NF-E2-Related Factor 2 | 2 | 2021 | 373 | 0.33 | Why? |
| Anaphylaxis | 3 | 2021 | 940 | 0.32 | Why? |
| Sublingual Immunotherapy | 2 | 2020 | 88 | 0.24 | Why? |
| Pollen | 2 | 2021 | 137 | 0.22 | Why? |
| TRPV Cation Channels | 1 | 2021 | 88 | 0.20 | Why? |
| Spices | 1 | 2020 | 130 | 0.20 | Why? |
| Infusions, Subcutaneous | 1 | 2018 | 36 | 0.19 | Why? |
| Pyroglyphidae | 1 | 2018 | 52 | 0.19 | Why? |
| Placebo Effect | 1 | 2018 | 108 | 0.18 | Why? |
| Antigens, Plant | 1 | 2018 | 40 | 0.18 | Why? |
| Neuraminic Acids | 1 | 2017 | 18 | 0.18 | Why? |
| Stearoyl-CoA Desaturase | 1 | 2017 | 13 | 0.18 | Why? |
| Bee Venoms | 1 | 2017 | 43 | 0.17 | Why? |
| Technology, Pharmaceutical | 1 | 2018 | 82 | 0.17 | Why? |
| Drug Dosage Calculations | 1 | 2018 | 243 | 0.16 | Why? |
| Biological Products | 3 | 2021 | 2331 | 0.16 | Why? |
| Conjunctivitis, Allergic | 1 | 2017 | 94 | 0.16 | Why? |
| Economics, Pharmaceutical | 1 | 2016 | 61 | 0.15 | Why? |
| Fatty Acids | 1 | 2017 | 238 | 0.15 | Why? |
| Environment, Controlled | 1 | 2017 | 129 | 0.15 | Why? |
| Common Cold | 1 | 2021 | 645 | 0.14 | Why? |
| Immunoglobulin E | 4 | 2020 | 557 | 0.14 | Why? |
| Allergists | 3 | 2021 | 266 | 0.14 | Why? |
| Colitis | 1 | 2017 | 266 | 0.13 | Why? |
| Farmers | 1 | 2017 | 280 | 0.13 | Why? |
| Quality Control | 1 | 2018 | 628 | 0.13 | Why? |
| Rhinitis | 1 | 2021 | 626 | 0.13 | Why? |
| Sinusitis | 1 | 2021 | 649 | 0.13 | Why? |
| Terminology as Topic | 1 | 2018 | 546 | 0.12 | Why? |
| Inhalation Exposure | 1 | 2017 | 405 | 0.12 | Why? |
| Interleukin-17 | 1 | 2017 | 602 | 0.12 | Why? |
| Food Hypersensitivity | 1 | 2017 | 397 | 0.11 | Why? |
| Practice Guidelines as Topic | 5 | 2018 | 15421 | 0.11 | Why? |
| Immune Tolerance | 1 | 2016 | 608 | 0.11 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.10 | Why? |
| Cost-Benefit Analysis | 2 | 2017 | 2259 | 0.10 | Why? |
| Respiratory Tract Diseases | 1 | 2017 | 1061 | 0.09 | Why? |
| Diet | 1 | 2020 | 2052 | 0.09 | Why? |
| Academies and Institutes | 2 | 2020 | 539 | 0.08 | Why? |
| Humans | 42 | 2022 | 930598 | 0.08 | Why? |
| Peptides | 1 | 2018 | 2513 | 0.08 | Why? |
| Consensus | 2 | 2021 | 6345 | 0.07 | Why? |
| Europe | 5 | 2020 | 12702 | 0.07 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Brassica | 1 | 2021 | 66 | 0.05 | Why? |
| Antioxidants | 2 | 2021 | 1593 | 0.05 | Why? |
| Fermentation | 1 | 2020 | 156 | 0.05 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3832 | 0.05 | Why? |
| Adrenal Cortex Hormones | 3 | 2021 | 6537 | 0.05 | Why? |
| Epinephrine | 1 | 2021 | 323 | 0.05 | Why? |
| Betula | 1 | 2018 | 10 | 0.05 | Why? |
| Administration, Sublingual | 1 | 2018 | 41 | 0.05 | Why? |
| Precision Medicine | 2 | 2019 | 1477 | 0.05 | Why? |
| Disease Resistance | 1 | 2020 | 236 | 0.05 | Why? |
| Animals | 5 | 2018 | 78931 | 0.04 | Why? |
| Information Technology | 1 | 2021 | 278 | 0.04 | Why? |
| Vegetables | 1 | 2020 | 340 | 0.04 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.04 | Why? |
| Nasal Polyps | 1 | 2021 | 221 | 0.04 | Why? |
| Polyethylene Glycols | 1 | 2021 | 574 | 0.04 | Why? |
| Th2 Cells | 1 | 2020 | 680 | 0.04 | Why? |
| Respiratory Hypersensitivity | 1 | 2017 | 103 | 0.04 | Why? |
| Administration, Intranasal | 1 | 2020 | 1132 | 0.04 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.04 | Why? |
| Biological Factors | 1 | 2019 | 276 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2017 | 647 | 0.04 | Why? |
| Administration, Inhalation | 1 | 2021 | 1647 | 0.04 | Why? |
| Proof of Concept Study | 1 | 2017 | 696 | 0.04 | Why? |
| Reactive Oxygen Species | 1 | 2020 | 1136 | 0.03 | Why? |
| Down-Regulation | 1 | 2021 | 1416 | 0.03 | Why? |
| Complement Activation | 1 | 2021 | 949 | 0.03 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.03 | Why? |
| Forced Expiratory Volume | 1 | 2017 | 632 | 0.03 | Why? |
| Eosinophils | 1 | 2020 | 848 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Chemotaxis, Leukocyte | 1 | 1992 | 82 | 0.03 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.03 | Why? |
| Up-Regulation | 1 | 2021 | 2249 | 0.03 | Why? |
| Secondary Prevention | 1 | 2017 | 762 | 0.03 | Why? |
| Lipid Metabolism | 1 | 2017 | 572 | 0.03 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| United States | 4 | 2021 | 46150 | 0.03 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.03 | Why? |
| Adolescent | 3 | 2018 | 86841 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Primary Prevention | 1 | 2017 | 778 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2017 | 1755 | 0.03 | Why? |
| Oxidative Stress | 1 | 2021 | 2050 | 0.02 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.02 | Why? |
| Adult | 5 | 2021 | 244371 | 0.02 | Why? |
| Proteomics | 1 | 2018 | 2481 | 0.02 | Why? |
| Mice | 2 | 2017 | 21357 | 0.02 | Why? |
| Young Adult | 1 | 2018 | 93724 | 0.02 | Why? |
| Health Policy | 2 | 2017 | 6242 | 0.02 | Why? |
| Genomics | 1 | 2018 | 3118 | 0.02 | Why? |
| Patient Care Team | 1 | 2021 | 3556 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Quality of Life | 2 | 2018 | 9820 | 0.02 | Why? |
| Environmental Exposure | 1 | 2017 | 1558 | 0.02 | Why? |
| Male | 5 | 2021 | 367725 | 0.02 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2018 | 4002 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.02 | Why? |
| Child | 3 | 2021 | 70012 | 0.02 | Why? |
| Epithelial Cells | 1 | 2017 | 3508 | 0.02 | Why? |
| Lymphocytes | 1 | 2017 | 3056 | 0.02 | Why? |
| Sputum | 1 | 1992 | 1720 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.02 | Why? |
| Signal Transduction | 1 | 2020 | 7207 | 0.02 | Why? |
| Health Services Needs and Demand | 1 | 2018 | 3419 | 0.02 | Why? |
| Female | 4 | 2018 | 380317 | 0.02 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Triage | 1 | 2021 | 7151 | 0.01 | Why? |
| Bacteria | 1 | 1992 | 1897 | 0.01 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.01 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Aged | 2 | 2021 | 215776 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Treatment Outcome | 1 | 2017 | 51732 | 0.01 | Why? |
| Middle Aged | 3 | 2018 | 270681 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |
| Risk Factors | 1 | 2018 | 71621 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2022 | 51949 | 0.01 | Why? |
| Leukocytes, Mononuclear | 1 | 1992 | 2115 | 0.00 | Why? |
Jutel's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(152)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(476)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_